As a consequence of the aging population and the increasing prevalence rates for conditions such as type 2 diabetes and chronic kidney disease (CKD), management of hypertension will be focusing more and more on the high-risk patient. Clinical practice guidelines for managing hypertension in the United States recommend a target blood pressure (BP) o130/80 mm Hg in patients with diabetes or CKD, notably lower than the 140/90-mm Hg threshold for the general hypertensive population. However, the optimal timeframe from initiation of antihypertensive therapy to attaining these levels of BP control and influencing cardiovascular outcomes is not as well defined. Overall, a series of landmark BP intervention trials in patients with hypertension and additional cardiovascular risk factors collectively support that achieving prompt BP control, ideally within 1-3 months, translates into improved cardiovascular outcomes. Although the consistency of the findings is encouraging, the strength of this conclusion is limited by the available data, which were derived from studies not designed to determine the definition or benefits of early BP reduction. In several of these studies, using a treatment approach with initial monotherapy or combination therapy has clearly demonstrated pronounced BP lowering and high BP control rates within an intensive timeframe of 3-6 months of therapy. Although these studies were not conducted exclusively in high-risk patients, subgroup analyses have demonstrated that the observed outcomes in the overall study populations apply to the diabetic and CKD subsets.
Introduction
Hypertension affects 470 million Americans aged X20 years, or roughly 1 in 3 adults, 1 and is associated with significant morbidity and mortality given the strength of its relationship with cardiovascular (CV) disease. 2, 3 Hypertension is known to potentiate the morbidity/mortality risk associated with the various individual CV disease risk factors, including the metabolic syndrome, dyslipidemia, chronic kidney disease (CKD), diabetes, and aging. 2 Since the first landmark blood pressure (BP) intervention trials were published in the 1960s and 1970s, evidence of the CV benefit of early and intensive BP management has been accumulating. Such evidence has contributed to the establishment of treatment goals-that is, systolic BP (SBP)/ diastolic BP (DBP) o140/90 mm Hg for most patients and SBP/DBP o130/80 mm Hg for those with diabetes or CKD (of note, the lower target is recommended per Joint National Committee 7 but not in recently updated European guidelines [2] [3] [4] )-and the recommendation that BP management strategies be started promptly on diagnosis of hypertension. Two or more antihypertensive agents are typically required to attain BP targets, with consensus guidelines for hypertension recommending first-line combination therapy in certain patients, such as those with diabetes and a BP420/ 10 mm Hg above the target level or in other circumstances warranting prompt BP reduction. 2, 3, 5 Upfront combination therapy has a greater propensity than monotherapy for achieving BP goals in patients with diabetes or the metabolic syndrome, as supported by subgroup analyses of clinical trials of angiotension receptor blocker (ARB)-based antihypertensive regimens. 6, 7 In the Study of Hypertension and the Efficacy of Lotrel in Diabetes (SHIELD), for example, BP goal at 3 months was achieved by 63% of patients who started on combination therapy compared with only 37% on monotherapy (Po0.01). 8 The benefits of intensive BP management are well established. In addition, there is a potential psychological advantage to timely BP control, which could translate into better long-term control. However, in clinical practice, control of hypertension remains suboptimal. 9 Although there is a vast body of literature stemming from the numerous BP intervention trials published to date, few reports allow for an assessment of the benefits and risks of early versus late BP control. Herein, we explore the optimal timeframe for target BP achievement by considering a selection of landmark trials that illustrate benefits of early and intensive BP management, highlighting available data specific to high-risk patients such as those with diabetes or CKD.
What is the evidence supporting beneficial outcomes for achieving BP control within months of initiating therapy?
Although the study results considered below allow for some exploration of the impact of early BP control, we acknowledge upfront the limitations pertaining to the available data, which are from clinical trials designed to evaluate the relative effects of different antihypertensive regimens on BP control and CV outcomes-not the relative outcomes associated with early versus late BP control. In addition, given that the majority of patients in these studies had been previously treated for hypertension, the extent to which the findings would apply to first-line antihypertensive therapy is not altogether clear. Overall, these limitations underscore the challenges of defining 'early BP control' and its associated impact on CV outcomes and may explain, in part, why such a definition is currently lacking. We are not aware of any completed, ongoing, or planned clinical trial in hypertensive patients with the primary objective of determining a specific target timeframe for achieving BP goals and associated CV outcomes. Such a trial would pose major and potentially insurmountable challenges from a study design standpoint given the complexity of ensuring sufficient statistical power, an adequate study duration for accumulating CV events, the accrual of a study population at high enough CV risk, and efficacy of the antihypertensive regimen(s) over the entire dosing interval. [10] [11] [12] The Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT), albeit not intentionally designed to assess the relative benefits of early versus late BP control, is one of the earliest contemporary trials that provides insight into this issue. In the original report of ALLHAT, which demonstrated that a diuretic (chlorthalidone) was as effective as an angiotensin-converting enzyme inhibitor (ACEI; lisinopril) or a calcium channel blocker (CCB, amlodipine) regarding the primary endpoint (combined fatal coronary heart disease and non-fatal myocardial infarction) while offering some advantages in secondary outcomes, it was evident that the most dramatic mean SBP reductions during the first 6 months of the trial were in the diuretic arm. 13 A particularly noteworthy finding from prespecified subgroup analyses was that black participants had a 40% increased risk of stroke if they received the ACEI rather than the diuretic. 13 In a subsequent report based on further analyses that stratified patients according to gender and race (black versus non-black), and focused on the ACEI and CCB arms, suboptimal BP-lowering effects for lisinopril were evident among black men and women. 14 Black ACEI recipients did not experience the sharp, pronounced BP reductions achieved by their non-black counterparts during the first 6 months of ALLHAT ( Figure 1 ) and had significantly higher rates of stroke when compared with CCB-treated black patients.
Whereas data derived from ALLHAT suggest that effective BP lowering during the first 6 months of antihypertensive therapy is a clinical determinant of stroke-related outcomes, advantages for improved BP control as early as 1 month post-initiation were seen in the Valsartan Antihypertensive Long-term Use Evaluation (VALUE)-a randomized, doubleblind study of CCB (amlodipine)-or ARB (valsartan)-based therapy in 15 245 hypertensive patients at high CV risk (4823 had type 2 diabetes; 3435 had proteinuria). 15, 16 The primary outcome, a composite of cardiac mortality and morbidity, did not differ significantly between the two groups; however, several secondary outcomes favored the CCB group, including myocardial infarction and stroke. 15 The most striking difference between the two arms was with respect to early SBP reduction, which was more pronounced in the CCB arm at 1 month (À4.0 mm Hg versus ARB) and 6 months (À2.1 mm Hg versus ARB) (both Po0.0001).
17 Attaining SBP o140 mm Hg within 6 months, regardless of the antihypertensive regimen, was identified as the primary determinant of event rates except for myocardial infarction. Furthermore, 'immediate' responders, defined as (1) previously treated patients who did not have an SBP increase when switched to study drug or (2) previously untreated patients with an initial SBP decrease of X10 mm Hg within the first month, had significant (Po0.05) advantages compared with 'non-immediate' responders with respect to combined cardiac events, stroke, and all-cause mortality. 17 Clinical trial data are also available to support efforts to achieve prompt BP reductions during the first 3 months of initiating a new antihypertensive regimen, mainly by inference that differences in specific study outcomes at least partially stemmed from BP-related differences at early time points. The Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA) was a randomized, controlled study of CCB (amlodipine)-versus b-blocker (atenolol)-based therapy in 19 257 hypertensive patients with X3 other CV risk factors. 18 Although the number of patients in the primary analysis (combined endpoint of non-fatal myocardial infarction and fatal coronary heart disease) were not significantly different between the two groups, between-group differences on six of the seven secondary outcomes favored CCB-based therapy including fatal and non-fatal stroke, total CV events and procedures, and all-cause mortality (Po0.05). The investigators attributed such differences to the prompt BP reductions observed during the first year of follow up in the CCB group. Throughout the study, the BP levels were lower in patients assigned to the CCB-based regimen. The differences in BP between treatments were largest at 3 months (À5.9/À2.4 mm Hg). At the 6-year followup, BP reductions were À27.5/À17.7 mm Hg for CCB-based therapy and À25.7/À15.6 mm Hg for b-blocker-based therapy. 18 This suggests that early BP control positively impacts longer-term CV outcomes, perhaps due to some physiologic 'memory'
mechanism not yet understood. ASCOT-BPLA analyses of prespecified subgroups demonstrated that significant advantages for the CCB-based regimen also applied to the subsets of patients with diabetes, metabolic syndrome, or renal dysfunction, or who were aged 460 years. 18 Unadjusted hazard ratios for total CV events and procedures, all favoring the CCB arm, were 0.87 in the diabetic subset, 0.84 in the metabolic syndrome subset, and 0.83 both in the renal dysfunction and age 460-year subsets (Po0.05). 18 Consistent with ASCOT-BPLA, benefits for achieving BP reductions within a 3-month timeframe had been previously documented in the Study on COgnition and Prognosis in the Elderly (SCOPE)-a randomized, double-blind study to assess the effect of an ARB on major CV events in 4964 hypertensive patients aged 70-89 years. 19 These elderly patients were randomized to receive candesartan or placebo and, 3 months post-randomization, additional Figure 1 ALLHAT: baseline and follow-up blood pressures by race and gender, illustrating that non-black amlodipine and lisinopril recipients (both men and women) experienced more profound blood pressure lowering effects during the first 6 months of follow-up when compared with black amlodipine and lisinopril recipients. DBP, diastolic blood pressure; SBP, systolic blood pressure. Reprinted from Leenen et al.
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antihypertensives could be added if SBP X160 mm Hg and DBPX90 mm Hg. After a 3.7-year mean follow up, the mean difference in BP lowering at the last study visit was 3.2/1.6 mm Hg in favor of the ARB (Po0.001), with a mean BP reduction of 21.7/10.8 versus 18.5/9.2 mm Hg for the control. ARB recipients had a non-significant 10.9% reduction in major CV event risk; however, their risk for non-fatal stroke was reduced by 27.8% (P ¼ 0.04), with a 23.6% reduced risk of all stroke approaching significance (P ¼ 0.056). 19 It has been postulated in the literature that these findings may be a consequence of immediate versus delayed antihypertensive therapy and associated BP control; that is, because the placebo group did not begin active therapy until 3 months after the candesartan group, it could be interpreted that placebo recipients had delayed treatment. 20 In SCOPE, the reductions in major CV events and stroke in the ARB group were seen across subgroups, including baseline diabetes. 21 Among the 313 ARB recipients with baseline diabetes, mean BP reduction was 5.1/1.2 mm Hg greater than that in the control group (BP reduction of À22.7/ À12.7 mm Hg for candesartan versus À17.7/ À11.5 mm Hg for control). There was no significant interaction between treatment and the diabetic/nondiabetic subgroups when evaluating major CV events or stroke. In the diabetic subset, ARB therapy reduced the risks of first major CV event, first nonfatal stoke, and first non-fatal or fatal stroke by 20%, 16%, and 10%, respectively. However, the relative risks were associated with wide 95% confidence intervals and were not found to be statistically significant, which the authors attributed to the small numbers of events and corresponding low statistical power for the various individual subgroups evaluated. 21 
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But are target BP levels attainable within a matter of months?
The studies discussed above and others [22] [23] [24] illustrate that substantial BP reductions and control rates are indeed attainable within 6 months or sooner. The recently published results of the Avoiding Cardiovascular events through COMbination therapy in Patients LIving with Systolic Hypertension (ACCOMPLISH) trial provide further evidence in this regard, both for the general hypertensive population and for patients with diabetes. ACCOMPLISH was unique in design in that it evaluated two fixed-dose combination antihypertensive regimens, randomizing 11 506 hypertensive patients at high CV risk to receive initial ACEI/CCB (benazepril/amlodipine) or ACEI/ diuretic (benazepril/hydrochlorothiazide) therapy. [25] [26] [27] In the primary outcome analysis, 9.6% of patients in the ACEI/CCB group and 11.8% in the ACEI/diuretic group experienced a CV event or CV-related death, translating into a 19.6% relative risk reduction for the former regimen (Po0.001). 26 The difference between the two groups in SBP was o1 mm Hg throughout the trial. 26 By Month 6, 73% of all patients had attained the target BP of o140/90 mm Hg, with a notably prompt BP decline occurring during the first 3 months. 25, 26 Control rates remained high (73% overall) and SBP/DBP remained low (132.7/74.7 mm Hg overall) at Month 12 and persisted throughout the study. 28 Adverse event rates were consistent with clinical experience with the individual agents, including a low incidence of hypotension (3% overall). 26 The results of ACCOMPLISH have applicability to the diabetic population given the notably high rate of baseline type 2 diabetes in this particular trial. At enrollment, 60% of participants in ACCOMPLISH had been diagnosed with type 2 diabetes and 6% had renal disease. 26 BP was o140/90 mm Hg at baseline in 38% of patients in each of these subgroups, increasing to 72.5% and 70.8% in patients with diabetes and CKD, respectively, at Month 6. 25, 29 Furthermore, 43% of patients with diabetes and 40% with CKD achieved a BP o130/80 mm Hg by Month 6, which albeit recommended per the protocol was not mandatory per the study requirements. 25, 29 Mean SBP after 6 months approached 130 mm Hg in both subsets (132.8 mm Hg diabetes; 133.5 mm Hg CKD), suggesting that most patients can reach this intensive goal in a short timeframe. 25 Additional data are available for the diabetic subset, with BPo130/80 mm Hg documented in 36% of patients by Month 3 29 and in 43% at Month 12 (including 48% and 73% with SBP o130 mm Hg and DBPo80 mm Hg, respectively). 28 A multivariate analysis revealed that several patientspecific factors were significant for achieving BPo130/80 mm Hg in patients with diabetes, including lower baseline SBP, pretreatment with fewer antihypertensive agent classes, and history of coronary revascularization. 28 The prompt BP-lowering ability of fixed-dose dual combination antihypertensive therapy has also been demonstrated in an exclusively diabetic population, with 11 140 patients with type 2 diabetes having participated in the placebo-controlled Action in Diabetes and Vascular disease: preterAx and diamicroN-MR-Controlled Evaluation (ADVANCE) trial. 30 The fixed-dose ACEI/diuretic combination of perindopril/indapamide was significantly more effective than placebo with respect to the primary endpoint of preventing a macrovascular or microvascular event, as well as for the secondary endpoints of CV disease-related mortality and all-cause mortality. The active run-in phase of ADVANCE is of interest for the present discussion of prompt BP control, as both groups received 6 weeks of perindopril/indapamide and experienced a reduction in mean BP to 137/78 mm Hg before initiating the randomized treatment phase. Among patients randomized to the ACEI/diuretic regimen, mean BP was 145/81 mm Hg at baseline and fell to 137/78 mm Hg at the end of the 6-week run-in and then to 133/76 mm Hg at Month 6 (versus a rise to 140/78 mm Hg with placebo). SBP ranged from 134 to 136 mm Hg and DBP from 73 to 76 mm Hg when considering subsequent 6-month measurements out to 5 years post-randomization. Of note, unlike for ACCOMPLISH, the proportion of patients achieving the diabetes-specific BP target of o130/80 mm Hg was not reported for ADVANCE.
Conclusions and clinical implications
Prompt BP control-within 6 months but ideally within 1 to 3 months-appears to confer improved outcomes in hypertensive patients, particularly those with stage 2 hypertension and/or at high CV risk. Current hypertension treatment guidelines recommend BP goals of o140/90 mm Hg (o130/ 80 mm Hg in patients with diabetes per Joint National Committee 7, with recently updated European guidelines citing insufficient evidence for this lower threshold, 4 ) although there is recent controversy over whether lowering BP beyond these target levels provides any benefit. 31, 32 Whereas data from ALLHAT lend support to the 6-month timeframe, BP reductions achieved within 1 month in the CCB arm of the VALUE trial likely brought about the lower rates of secondary outcomes seen in that treatment group. Similarly, improved secondary outcomes in the amlodipine arm of ASCOT-BPLA and a reduced stroke risk in the candesartan arm of SCOPE appeared to stem from BP intervention and control within the first 3 months of these trials. Data suggest that early BP control may impart a physiologic 'memory' that manifests itself as outcomes benefits over the long term. Subgroup analyses of VALUE, ASCOT-BPLA, and SCOPE demonstrated that the beneficial effects seen in the overall study populations apply to particularly high-risk subsets, such as those with diabetes, CKD, or metabolic syndrome. The ACCOMPLISH trial, which had a study population with a high incidence of type 2 diabetes at baseline, and the ADVANCE trial in type 2 diabetes support that prompt BP reductions are attainable in the diabetic population. The results also suggest that initiating therapy with a combination of antihypertensive agents, including use of high-dose combinations has substantial potential for prompt attainment of BP goals in the high-risk hypertensive patient with diabetes and/or CKD.
We acknowledge that the conclusions regarding early BP control derived from ALLHAT, VALUE, ASCOT-BPLA, and SCOPE (studies not designed with the question of timing of BP control in mind) are based on imperfect data, yet the available evidence was notably consistent in supporting the ability of short-term BP reductions to attenuate CV outcomes. To our knowledge, there are no published data to support that achieving BP goals within 6 months or sooner has no effect or a negative effect on CV outcomes. In addition, in time-to-goal BP studies (such as SHIELD), there was no difference in the incidence of adverse events between more prompt and less prompt groups. 8, 33 Nevertheless, there has been long-standing discussion/debate and unresolved questions remain surrounding the 'J-curve' relationship between DBP levels and CV outcomes, with the potential for pronounced BP lowering to confer an increased risk of CV events in high-risk populations with preexisting alterations in organ perfusion, such as patients with coronary artery disease and/or of advanced age. 4, 12 In this regard, the patients at highest CV risk from uncontrolled BP may also be those at highest CV risk from profound BP lowering-posing a clinical challenge for which the importance of a cautious, highly individualized management plan cannot be overstated. As there is no precise definition of 'gradual' as it pertains to BP lowering, clinical judgment forms the cornerstone of decisions as to how fast and how far to lower BP in individual patients. We conclude that, based on the available data, control of BP based on individualized needs may provide more opportunity for CV risk reduction, particularly in higher-risk groups for vascular disease. Future studies are needed to establish the benefit:risk ratio of more prompt BP control on the overall risk of CV events.
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